Placental Pathology and Inflammatory Factor Analysis of OAPS

Last updated: May 12, 2022
Sponsor: Peking University People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Thrombosis

Platelet Disorders

Antiphospholipid Syndrome

Treatment

N/A

Clinical Study ID

NCT05378516
yjjbear2022
  • Ages 18-50
  • Female
  • Accepts Healthy Volunteers

Study Summary

This investigation is on placental pathological changes and inflammatory factors associated with obstetric antiphospholipid syndrome.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. pregnant women with antiphospholipid syndrome (diagnosed by experts with clinicalevidence) and healthy pregnant women without antiphospholipid syndrome as a controlgroup
  2. consent to join this study and finish the informed consents

Exclusion

Exclusion Criteria: pregnant women with other autoimmune diseases

Study Design

Total Participants: 40
Study Start date:
January 01, 2022
Estimated Completion Date:
December 31, 2023

Study Description

  1. To clarify the correlation between antiphospholipid antibody, ACC1 expression level, Treg cell and placental pathological changes associated with antiphospholipid syndrome. 2. Reveal that antiphospholipid antibodies affect Treg cell differentiation through the key enzyme of lipid metabolism ACC1.

Connect with a study center

  • PekingUPH

    Pekin,
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.